Archive

  • Select all
    |
  • PAN Zi-ye
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Psoraleae fructus is dried mature fruit of Psoralea corylifolia L., a plant from the Fabaceae family, and has various therapeutic effects, including warming the kidneys and assisting yang, relieving asthma, warming spleen and stopping diarrhea. However, psoraleae fructus has raised concerns regarding its medication safety due to its hepatotoxic side effects. This article mainly reviews the relationship between psoraleae fructus and liver injury, its hepatotoxic components, hepatotoxic characteristics, and methods to reduce its toxicity, aiming to provide reference for the safe and rational use of psoraleae fructus.
  • YU Jun-ru, CHEN Chen
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the pharmaceutical care process in antifungal treatment for a patient with gastric stromal tumor complicated by Candida albicans infection in the hospital, and provide reference for the rational selection of antibacterial drugs and medication safety of imatinib. Methodsand Results: The patient (male, 64 years old) was admitted with "lower back pain" and treated with imatinib due to gastric stromal tumor for a long time. The outpatient thoracolumbar MRI suggested possible vertebral infectious lesions, leading to empirical treatment with cefoperazone-sulbactam sodium. On the 5th day of hospitalization, Candida albicans was identified in thoracic puncture fluid examination, prompting a switch to caspofungin. Three days later, based on drug susceptibility results, caspofungin was adjusted to fluconazole. However, three days after the adjustment, the patient's lower back pain worsened and high-sensitivity C-reactive protein (CRP) level increased again. After discussion between the physician and the pharmacist, it was adjusted back to caspofungin. On the 30th day, the patient underwent thoracic vertebral lesion debridement. On the 46th day, his condition significantly improved, infection indicators notably decreased. After consultation with a pharmacist, considering potential drug interactions with imatinib, a switch to oral fluconazole sequential therapy was recommended. Conclusion: For patients with unexplained infections, clinical pharmacists should assist physicians in early pathogen identification to initiate targeted treatment, and adjust the therapeutic regimen timely based on the effect of anti-infective therapy. Additionally, attention should be paid to interactions with other medications to ensure the medication safety of patients.
  • MO Yu-na
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the pharmaceutical care process in anti-infective treatment for a hemodialysis patient complicated by catheter-related infection and pulmonary infection, and provide reference for the anti-infective treatment of clinical dialysis patients. Methodsand Results: The patient was admitted with "chills for 1 hour during dialysis". Upon admission, the examination revealed erythema and swelling at the catheter insertion site, with a white blood cell count of 16.71×109/L and a neutrophil percentage of 93.40%, suggesting catheter-related infection, so anti-infective treatment with cefazolin was initiated. On the second day of hospitalization, a CT scan revealed pulmonary infection. After consultation with a clinical pharmacist, considering the common pathogen spectrum for both catheter-related infection and pulmonary infection as well as the patient's baseline renal function, the treatment was switched to piperacillin-tazobactam sodium, with a dosage of 2.25 g every 12 hours based on the patient's creatinine clearance. This recommendation was adopted by the physician. On the fifth day, blood cultures of the patient identified Stenotrophomonas maltophilia which was sensitive to piperacillin-tazobactam sodium. Conclusion: When developing an empirical anti-infective treatment regimen for complicated infections in hemodialysis patients, clinicians should first consider the common pathogen spectrum associated with infections. Additionally, the treatment regimen should be optimized and adjusted based on clear etiological results and tailored to the patient's liver and renal function to ensure the therapeutic efficacy.
  • HE Lian, JIANG Wen-qing, YUN Yuan, ZHANG Qian
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the occurrence and management of moxifloxacin-induced QT interval prolongation of a patient, and provide reference for the clinical safe use of moxifloxacin. Methodsand Results: A patient (male, aged 76) was admitted due to cough and sputum for several days and worsening. Upon admission, chest CT, lung auscultation, and infection indicators suggested pulmonary infection. He was treated with moxifloxacin and cefoperazone-sulbactam sodium for anti-infective therapy. On day 2, electrocardiogram (ECG) monitoring showed normal (QT/QTc 388/439 ms). On day 3, the patient complained of chest tightness, and ECG revealed QT interval prolongation (QT/QTc 467/529 ms). Moxifloxacin was discontinued after 14 days. Two days later, ECG showed normal (QT/QTc 358/421 ms). A subsequent Naranjo scale assessment indicated a "probable" association between moxifloxacin and QT interval prolongation. Conclusion: QT interval prolongation is a common adverse drug reaction of moxifloxacin. The corresponding monitoring should be conducted during clinical use of moxifloxacin to allow for timely disposal in case of risks, so as to ensure the medication safety of patients.
  • YANG Bo, WANG Jie
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the compatibility and contraindication of papaverine hydrochloride and coping strategies through literature retrieval, and provide reference for clinical safe use of papaverine hydrochloride. Methods: A literature retrieval was conducted using keywords such as "papaverine", "compatibility and contraindication", "stability" in databases such as CNKI, Wanfang Data, and Chongqing VIP. Relevant information on drugs with compatibility and contraindication was collected from the literature, and safe medication strategies for using papaverine hydrochloride with these drugs were explored. Results: A total of 19 articles related to the compatibility and contraindication of papaverine hydrochloride were found in databases, involving 11 categories of 27 drugs, 20 of which had been experimentally validated. Among 11 categories, the main drug types were digestive system drugs (6), anti-infective drugs (5), traditional Chinese medicine injections (4), and cardiovascular system drugs (3). After combining papaverine hydrochloride with 27 drugs, the primary feature was appearance of turbidity, flocculent substances or precipitation. Of these, 16 drugs were clearly associated with compatibility and contraindication issues related to pH. For these 27 drugs, it is recommended to avoid co-administration or sequential infusion with papaverine hydrochloride. If sequential infusion is necessary, appropriate solvents should be selected for thorough flushing. Conclusion: Papaverine hydrochloride is a weakly alkaline drug with strong acidic properties, and its stability is closely related to pH of the solution. When combining it with other drugs or performing sequential infusion, it is essential to consider pH of drugs to avoid any adverse event associated with compatibility and contraindication, so as to ensure the medication safety of patients.
  • WANG Dan-dan, MENG Jia-jia, MENG Ping, DOU Zhi-hua
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the pharmaco-epidemiological characteristics of drug-induced liver injury (DILI) reports in Nantong from 2012 to 2021, and provide reference for clinical responses to DILI in the future. Methods: 877 adverse drug reaction (ADR) reports concerning DILI from the system of Nantong Adverse Drug Reaction Monitoring Center from January 2013 to December 2022 were selected as research materials. The relevance evaluation on the involved drugs and DILI and the distribution features of drug types were collected. Results: Among 877 ADR reports, the relevance between the drugs and DILI was mainly classified as "very likely" (517 cases, 58.95%), "possible" (349 cases, 39.79%), and "definite" (11 cases, 1.25%). The drugs inducing DILI were primarily antitumor drugs (268 cases, 30.56%), anti-infective drugs (194 cases, 22.12%), psychotropic drugs (176 cases, 20.07%), and cardiovascular drugs (133 cases, 15.17%). The main types of antitumor drugs were tubulin inhibitors (94 cases) and platinum complexes (46 cases), the main types of anti-infective drugs were antituberculosis drugs (105 cases) and antibacterial drugs (65 cases), the main type of psychotropic drugs was antipsychotic medications (169 cases), and the main type of cardiovascular drugs was lipid-lowering agents (121 cases). Conclusion: Antitumor drugs, anti-infective drugs, psychotropic drugs and cardiovascular drugs are the primary drugs inducing DILI. Clinical monitoring and education on these drug categories and their key drugs should be strengthened to improve the response to DILI, so as to ensure the medication safety of patients.
  • ZHAO Fang-li, ZHOU Xiao-xia, CHEN Jun-yi, ZHU Li-hong
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To explore the mechanism of action of Shashen Maidong decoction in treatment of viral pneumonia using network pharmacology and molecular docking technology, and provide reference for further research on Shashen Maidong decoction. Methods: The active ingredients and their effect targets in Shashen Maidong decoction were obtained from the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP), and gene targets associated with viral pneumonia were obtained from databases such as GeneCards, OMIM. The common targets between the active ingredients and viral pneumonia were obtained. Protein-protein interaction (PPI) network analysis was performed to screen for core targets, and Gene Ontology (GO) functional analysis and KEGG pathway enrichment analysis were used to screen the biological processes and related pathways through which Shashen Maidong decoction may exert effects on viral pneumonia. Finally, molecular docking technology was used to analyze the binding affinity between key ingredients and their targets. Results: A total of 124 active ingredients and 248 corresponding effect targets of Shashen Maidong decoction were screened from TCMSP. 524 gene targets associated with viral pneumonia were obtained from GeneCards, OMIM and other databases. Among them, there were 75 common targets. PPI network analysis of 75 common targets yielded 34 core targets. GO functional analysis suggested that Shashen Maidong decoction may exert anti-viral pneumonia effects by regulating inflammation and cell activity. KEGG pathway enrichment analysis revealed that Shashen Maidong decoction may act for treatment of viral pneumonia through pathways such as AGE-RAGE signaling pathway in diabetic complications, T cell receptor signaling pathway, NF-κB signaling pathway, IL-17 signaling pathway, TNF signaling pathway, and trypanosomiasis signaling pathway. Molecular docking results showed that six key ingredients of Shashen Maidong decoction, quercetin, kaempferol, beta-carotene, naringenin, arachidonic acid, and stigmasterol, demonstrated good binding affinity with the key targets of viral pneumonia, including tumor necrosis factor (TNF), interleukin-6 (IL-6), IL-1β, protein kinase B (AKT1), albumin (ALB), and Chemokine (CC-motif) ligand 2 (CCL2), with binding energies all less than -5 kJ/mol. Conclusion: Quercetin, kaempferol, beta-carotene, naringenin, arachidonic acid, and stigmasterol may be the main active components of Shashen Maidong decoction in the treatment of viral pneumonia, while TNF, IL-6, IL-1β, AKT1, ALB, and CCL2 may be its primary effect targets.
  • WU Shan-shan, ZHAO Zhan, ZHANG Xiao-li, HUNANG Shu-xian, HUNANG Zhong-han, HE Chun-ling
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the epidemiological characteristics of children with macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia in our hospital, and provide reference for the clinical treatment of children with MRMP pneumonia. Methods: 14 children with MRMP pneumonia admitted to Nanning Hospital of Traditional Chinese Medicine between August and October in 2023 were selected as study subjects. Information such as age, gender, imaging examination results, etiological examination results, infection indicators, medication use, length of hospital stay, and outcomes was collected to analyze the clinical features of children with MRMP pneumonia. Results: Among 14 children with MRMP pneumonia (8 boys and 6 girls), all presented with fever and cough upon admission, and imaging examination revealed pulmonary inflammation. No obvious abnormality was found as for white blood cell count and neutrophil percentage. Most children had elevated C-reactive protein (CRP) level, with one child's CRP above 100 mg/L, while the others remained below 50 mg/L. All children were treated with azithromycin, with 8 receiving sequential therapy and 6 switched to doxycycline. Children who switched to doxycycline had a slightly shorter hospital stay compared to those with sequential therapy ((8.5±1.0) days vs (9.3±2.1) days, P=0.432), but their course of medication was significantly shorter than those with sequential therapy ((11.7±1.6) days vs (16.3±1.9) days, P<0.001). 14 children resolved cough symptoms completely and did not require readmission. Conclusion: Children with MRMP pneumonia commonly present with fever, cough, and patchy high-density lung lesions, and severe cases may progress to lung consolidation. Azithromycin remains effective in treating MRMP pneumonia, though the total course of medication tends to be longer. For children with rapid disease progression or insufficient symptom improvement, early use of second-line drugs can reduce the course of medication.